Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721

Crockett, Thomas R. and Scott, Gillian A. and McGowan, Neil W.A. and Kane, Kathleen A. and Wainwright, Cherry L. (2001) Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. European Journal of Pharmacology, 432 (1). pp. 71-77. ISSN 0014-2999

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

The effects of the endothelin ETA, (BQ-123) and endothelin ETA/B (PD161721) receptor antagonists were investigated on ischaemia-induced arrhythmias and on the maximum following frequency. The study was carried out in Langendorff perfused rat hearts subjected to coronary artery occlusion in which the severity of arrhythmias, coronary perfusion pressure and heart rate were measured. The % incidence of ischaemia-induced irreversible ventricular fibrillation (ventricular fibrillation) was reduced significantly from 58%, in control rat hearts, to 0% (at 10(-7) and 10(-6) M PD161721 and 10(-6) M BQ-123 P < 0.05). Maximum following frequency was measured in guinea-pig isolated atria. In the presence of normal extracellular [K+], BQ-123 and PD161721, at 10(-6) M, significantly decreased the maximum following frequency from 9.0 +/- 0.7 to 7.2 +/- 0.4 and from 8.3 +/- 0.4 to 6.7 +/- 0.3 Hz, respectively (P < 0.05). These effects were not potentiated by raising the extracellular [K+] with the exception of 10(-9) M PD161721. In contrast, lignocaine's ability to reduce the maximum following frequency was greater in elevated (e.g. at 1.7 X 10(-4) M from 8.4 +/- 0.3 to 2.5 +/- 0.6 Hz) than in normal [K+] (from 9.0 +/- 0.3 to 4.9 +/- 0.5 Hz). In conclusion, both BQ-123 and PD161721 had an anti-fibrillatory effect in isolated rat hearts that may be due, at least in part, to an ability to reduce the maximum following frequency. This latter effect is unlikely to be due to Na+ channel blockade since it was not markedly potentiated by elevation of extracellular [K+].